ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Autoantibody(ies)"

  • Abstract Number: 2050 • ACR Convergence 2020

    Autoantibodies Targeting Complement Receptors C3aR and C5aR1 Are Decreased in ANCA-associated Vasculitis and Correlate with a Higher Relapse Rate

    Sebastian Klapa1, Antje Müller2, Andreas Koch3, Anja Kerstein-Staehle4, Wataru Kaehler3, Harald Heidecke5, Susanne Schinke6, Markus Huber-Lang7, Martin Nitschke8, Silke Pitann9, Christian Karsten10, Gabriela Riemekasten11 and Peter Lamprecht2, 1University of Lübeck and Institute of Experimental Medicine, Christian-Albrechts-University of Kiel c/o German Naval Medical Institute, Department of Rheumatology and Clinical Immunology, Luebeck, Germany, 2University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, 3Institute of Experimental Immunology, Christian-Albrechts-University Kiel, c/o German Naval Medical Institute, Kronshagen, Germany, 4University of Lübeck, Dept Rheumatology and Clinical Immunology, Luebeck, Germany, 5CellTrend GmbH, Luckenwalde, Germany, 6University of Lübeck, Department of Rheumatology and Clinical Immunology, Luebeck, Germany, 7Institute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, Ulm, Germany, 8Department of Internal Medicine I, Transplant Center, University of Lübeck, Luebeck, Germany, 9University of Lübeck, Department of Rheumatology and Clinical Immunology,, Luebeck, Germany, 10Institute of Systemic Inflammation Research, University of Lübeck, Luebeck, Germany, 11University of Lübeck, Department of Rheumatology and Clinical Immunology,, Lübeck, Germany

    Background/Purpose: Activation of the alternative and common terminal complement pathways has been shown in ANCA-associated vasculitis (AAV). Circulating titers of the anaphylatoxin C5a are increased…
  • Abstract Number: 0289 • ACR Convergence 2020

    Endogenous Interferon-β and Low IL-4R on Transitional B Cells Promotes Lupus Nephritis

    Fatima Alduraibi1, Huma Fatima1, W. Winn Chatham1, Hui-Chen Hsu1 and John Mountz2, 1University of Alabama at Birmingham, Birmingham, AL, 2University Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL

    Background/Purpose: We previously showed that B-cell endogenous interferon-beta (IFNβ) at the transitional (Tr) stage correlates with development of anti-Smith (anti-Sm) and renal disease as well…
  • Abstract Number: 0790 • ACR Convergence 2020

    Vitamin D Polygenetic Risk Score and the Association with RA Autoantibodies Among First-Degree Relatives of RA Subjects

    Elizabeth Bemis1, Kendra Young2, Jennifer Seifert3, Marie Feser4, Kevin D. Deane5, M Kristen Demoruelle6, James O'Dell7, Michael Weisman8, Peter Gregersen9, Richard Keating10, William Robinson11, Jane Buckner12, Carl Langefeld13, Joel Guthridge14, Judith James15, V Michael Holers4 and Jill Norris16, 1Colorado School of Public Health Anschutz Medical Campus, Aurora, CO, 2University of Colorado Denver, Aurora, CO, 3UC Denver, Littleton, CO, 4Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, 52 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, 6University of Colorado, Denver, CO, 7University of Nebraska Medical Center, Omaha, NE, 8Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, 95. Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, 10Scripps Clinic/Scripps Green Hospital, La Jolla, CA, 11Stanford University, Palo Alto, CA, 12Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, 13Wake Forest School of Medicine, Winston Salem, NC, 14Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Oklahoma Medical Research Foundation, Oklahoma City, 16Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, Colorado

    Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disease whose etiology remains largely unknown.  Vitamin D has been widely studied due to its association with…
  • Abstract Number: 1098 • ACR Convergence 2020

    Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis

    Iago Pinal-Fernandez1, Katherine Pak2, Albert Gil-Vila3, Andres Baucells4, Benjamin Plotz5, Maria Casal-Dominguez6, Assia Derfoul7, Maria Angeles Martinez4, Albert Selva-O'Callaghan3, Sara Sabbagh8, Frederick W. Miller1, Lisa G. Rider9, Lisa Christopher-Stine10 and Andrew Mammen6, 1National Institutes of Health, Bethesda, MD, 2NIAMS, NIH, Bethesda, MD, 3Vall d’Hebron Hospital, Barcelona, Spain, 4Sant Pau Hospital, Barcelona, Spain, 5Division of Rheumatology, New York University Langone Health, New York, NY, 6NIH, Bethesda, MD, 7NIAMS, NIH, Bethesda, 8Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Washington, DC, 9Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, 10Johns Hopkins University, Baltimore, MD

    Background/Purpose: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.Methods: In this longitudinal cohort study, anti-cortactin autoantibody tiers were…
  • Abstract Number: 1507 • ACR Convergence 2020

    Longitudinal Analysis of ANA Assay Performance in SLE from the SLICC Inception Cohort

    May Choi1, Ann Clarke2, Karen Costenbader3, Murray Urowitz4, John Hanly5, Caroline Gordon6, Yvan St. Pierre7, Sang-Cheol Bae8, Juanita Romero-Díaz9, F Jorge Sanchez-Guerrero10, Sasha Bernatsky11, Daniel Wallace12, David Isenberg13, Anisur Rahman14, Joan Merrill15, Paul Fortin16, Dafna Gladman17, Ian Bruce18, Michelle Petri19, Ellen M Ginzler20, Mary Anne Dooley21, Rosalind Ramsey-Goldman22, Susan Manzi23, Andreas Jönsen24, Graciela Alarcón25, Ronald F Van Vollenhoven26, Cynthia Aranow27, Meggan Mackay28, Guillermo Ruiz-Irastorza29, S. Sam Lim30, Murat Inanc31, Kenneth Kalunian32, Søren Jacobsen33, Christine Peschken34, Diane Kamen35, Anca Askanase36 and Marvin Fritzler37, 1Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2University of Calgary, Calgary, Canada, 3Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 4University Health Network, University of Toronto, Toronto, ON, Canada, 5Dalhousie University, Halifax, NS, Canada, 6University of Birmingham, Birmingham, England, United Kingdom, 7McGill University, Montreal, Canada, 8Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 9Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 10University Health Network/Sinai Health system, Toronto, ON, Canada, 11The Research Institute of the McGill University Health Centre, Montreal, ON, Canada, 12Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, 13Centre for Rheumatology, University College London and Department of Rheumatology, University College Hospital, London, United Kingdom, 14University College London, London, United Kingdom, 15Oklahoma Medical Research Foundation, Oklahoma City, 16CHU de Quebec - Universite Laval, Quebec, Canada, 17Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 18Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 19Johns Hopkins University School of Medicine, Timonium, MD, 20SUNY Downstate Health Sciences University, Brooklyn, 21University of North Carolina, Chapel Hill, NC, 22Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 23Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, 24Lund University, Lund, Sweden, 25Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, 26Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 27Feinstein Institutes for Medical Research, Manhasset, NY, 28Feinstein Institute for Medical Research, Manhasset, NY, 29Hospital Universitario Cruces, Barakaldo, Spain, 30Emory University, Atlanta, GA, 31Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 32University of California San Diego, La Jolla, CA, 33University of Copenhagen, Copenhagen, Denmark, 34Departments of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, 35Medical University of South Carolina, Charleston, SC, 36Columbia University College of Physicians and Surgeons, New York, NY, 37Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

    Background/Purpose: Anti-nuclear antibodies (ANA) are important biomarkers for the diagnosis and classification of systemic lupus erythematosus (SLE). However, emerging data from cross-sectional studies suggest variation…
  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology